Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...
"Patients who undergo surgery and end up developing post-surgical neuropathic pain, may experience debilitating complications that often are ... AV001 is a randomized, double-blind 42 week trial ...
The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...
TRV045 reversed thermal hyperalgesia, a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy ... It is indicated in adults for the management of acute pain severe ...